Insider Selling: Matthew G. Mcdevitt Unloads 16,000 Shares of BioMed Realty Trust Stock (BMR)
BioMed Realty Trust (NYSE:BMR) VP Matthew G. Mcdevitt unloaded 16,000 shares of BioMed Realty Trust stock on the open market in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $22.01, for a total value of $352,160.00. Following the completion of the sale, the vice president now directly owns 122,328 shares in the company, valued at approximately $2,692,439. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of BioMed Realty Trust (NYSE:BMR) traded up 1.83% on Wednesday, hitting $22.21. The stock had a trading volume of 2,704,120 shares. BioMed Realty Trust has a 1-year low of $17.90 and a 1-year high of $22.47. The stock’s 50-day moving average is $21.79 and its 200-day moving average is $20.99. The company has a market cap of $4.242 billion and a price-to-earnings ratio of 82.30.
BioMed Realty Trust (NYSE:BMR) last released its earnings data on Tuesday, August 5th. The company reported $0.40 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.36 by $0.04. The company had revenue of $171.16 million for the quarter, compared to the consensus estimate of $160.80 million. During the same quarter last year, the company posted $0.37 earnings per share. BioMed Realty Trust’s revenue was up 7.2% compared to the same quarter last year. On average, analysts predict that BioMed Realty Trust will post $1.52 earnings per share for the current fiscal year.
BMR has been the subject of a number of recent research reports. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of BioMed Realty Trust in a research note on Monday. They now have a $24.00 price target on the stock, up previously from $23.00. Separately, analysts at Jefferies Group raised their price target on shares of BioMed Realty Trust from $23.00 to $25.00 in a research note on Tuesday, July 22nd. Finally, analysts at MLV & Co
initiated coverage on shares of BioMed Realty Trust in a research note on Friday, June 27th. They set a “hold” rating and a $23.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $23.29.
BioMed Realty Trust, Inc operates as a real estate investment trust (NYSE:BMR), and the general partner of BioMed Realty, L.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.